Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward “precision” cancer therapy

References

• Acs G, Kiluk J, Loftus L, Laronga C (2013) Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas. Mod. Pathol. 26: 1451–1460.
   PubMed Web of Science ®Google Scholar
• Advani P, Cornell L, Chumsri S, Moreno-Aspitia A (2015) Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. Breast Cancer 22: 321–335.
   Google Scholar
• Afentakis M, Dowsett M, Sestak I, Salter J, Howell T, Buzdar A, Forbes J, Cuzick J (2013) Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study. Breast Cancer Res. Treat. 140: 253–262.
   PubMed Web of Science ®Google Scholar
• AGO Guidelines German S3 Guidelines for the Diagnosis, Treatment and Follow-up Care of Breast Cancer Update (2012) www.senologie.org/fileadmin/downloads/S3-Brustkrebs-v2012-OL-Langversion.pdf [accessed 12/05/2016].
   Google Scholar
• Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF (Breast Cancer Intergroup of North America) (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11: 55–65.
   PubMed Web of Science ®Google Scholar
• Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM (2012) Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res. Treat. 131: 413–424.
   PubMed Web of Science ®Google Scholar
• Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11: 155–168.
   PubMed Web of Science ®Google Scholar
• Amend K, Hicks D, Ambrosone CB (2006) Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res. 66: 8327–8330.
   PubMed Web of Science ®Google Scholar
• Amiri-Kordestani L, Wedam S, Zhang L, Tang S, Tilley A, Ibrahim A, Justice R, Pazdur R, Cortazar P (2014) First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin. Cancer Res. 20: 5359–5364.
   PubMed Web of Science ®Google Scholar
• Arango BA, Rivera CL, Glück S (2013) Gene expression profiling in breast cancer. Am. J. Transl. Res. 5: 132–138.
   PubMed Web of Science ®Google Scholar
• Ariga N, Suzuki T, Moriya T, Kimura M, Inoue T, Ohuchi N, Sasano H (2001) Progesterone receptor A and B isoforms in the human breast and its disorders. J. Cancer Res. 92: 302–308.
   Google Scholar
• Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, Andre F (2015) Precision medicine for metastatic breast cancer–limitations and solutions. Nat. Rev. Clin. Oncol. 12: 693–704.
   PubMed Web of Science ®Google Scholar
• Augustovski F, Soto N, Caporale J, Gonzalez L, Gibbons L, Ciapponi A (2015) Decision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis. Breast Cancer Res. Treat. 152: 611–625.
   PubMed Web of Science ®Google Scholar
• Baak JPA, Gudlaugsson E, Skaland I, Guo L, Klos J, Lende TH, Soiland H, Janssen EAM, Hausen A (2009) Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res. Treat. 115: 241–254.
   PubMed Web of Science ®Google Scholar
• Bamberger AM, Milde-Langosch K, Schulte HM, Loning T (2000) Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm. Res. 54: 32–37.
   PubMedGoogle Scholar
• Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Piña V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, Thompson KM, Uribe-Figueroa L, Baselga J, Beroukhim R, Polyak K, Sgroi DC, Richardson AL, Jimenez-Sanchez G, Lander ES, Gabriel SB, Garraway LA, Golub TR, Melendez-Zajgla J, Toker A, Getz G, Hidalgo-Miranda A, Meyerson M (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405–409.
   PubMed Web of Science ®Google Scholar
• Bartlett JM, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, Pedersen HC, Munro A, Kunkler IH, Campbell FM, Jack W, Kerr GR, Johnstone L, Cameron DA, Chetty U (2010) Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res. 12: R47.
   PubMed Web of Science ®Google Scholar
• Bartlett JM, Bloom KJ, Piper T, Lawton TJ, van de Velde CJ, Ross DT, Ring BZ, Seitz RS, Beck RA, Hasenburg A, Kieback D, Putter H, Markopoulos C, Dirix L, Seynaeve C, Rea D (2012) Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. J. Clin. Oncol. 30: 4477–4484.
   PubMed Web of Science ®Google Scholar
• Bartlett JM, Christiansen J, Gustavson M, Rimm DL, Piper T, van de Velde CJ, Hasenburg A, Kieback DG, Putter H, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW (2016) Validation of the IHC4 breast cancer prognostic algorithm Using multiple approaches on the multinational TEAM clinical trial. Arch. Pathol. Lab. Med. 140: 66–74.
   PubMed Web of Science ®Google Scholar
• Barton S, Zabaglo L, A’Hern R, Turner N, Ferguson T, O’Neill S, Hills M, Smith I, Dowsett M (2012) Assessment of the contribution of the IHC4+ C score to decision making in clinical practice in early breast cancer. Br. J. Cancer 106: 1760–1765.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM (Cleopatra Study Group) (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366: 109–119.
   PubMed Web of Science ®Google Scholar
• Baselga J, Im S-A, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiello-Gruszfeld A, Pistilli B, Tseng L-M, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Hachemi S, Le Mouhaër S, Di Tomaso E, Urban P, Massacesi C, Campone M (2016) PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HRþ/HER2e advanced breast cancer (BC): first results from the randomized, phase III BELLE-2 trial. Cancer Res. 76 (Suppl. 4): Abstract S6-01 2015 San Antonio Breast Cancer Symposium.
   PubMed Web of Science ®Google Scholar
• Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Seguí MÁ, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M (2012) PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BioMed Central Med. Genom. 5: 44.
   PubMed Web of Science ®Google Scholar
• Ben-Baruch NE, Bose R, Kavuri SM, Ma CX, Ellis MJ (2015) HER2-mutated breast cancer responds to treatment with single-agent neratinib, a second generation HER2/EGFR Tyrosine Kinase Inhibitor. J. Natl. Compr. Canc. Netw. 13: 1061–1064.
   PubMed Web of Science ®Google Scholar
• Benraad TJ, Geurts-Moespot J, Grøndahl-Hansen J, Schmitt M, Heuvel JJ, de Witte JH, Foekens JA, Leake RE, Brünner N, Sweep CG (1996) Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1Workshop. Eur. J. Cancer 32: 1371–1381.
   Web of Science ®Google Scholar
• Bergh J, Holmquist M (2001) Who should not receive adjuvant chemotherapy? J. Natl. Cancer Inst. Monogr. 2001: 103–108.
   Google Scholar
• Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 7: e1000279.
   PubMed Web of Science ®Google Scholar
• Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3: 224–237.
   PubMed Web of Science ®Google Scholar
• Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A, Reghellin D, Chilosi M, Bonetti F (2008) HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am. J. Clin. Pathol. 129: 907–911.
   PubMed Web of Science ®Google Scholar
• Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, Van’t Veer LJ, van de Vijver MJ (2009) Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res. Treat. 117: 483–495.
   PubMed Web of Science ®Google Scholar
• Bueno-de-Mesquita JM, van Harten WH, Retel VP, van’t Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC (2007) Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol. 8: 1079–1087.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J. Clin. Oncol. 32: 2255–2269.
   PubMed Web of Science ®Google Scholar
• Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM, d’Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ (TRANSBIG Consortium) (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst. 98: 1183–1192.
   PubMed Web of Science ®Google Scholar
• Calhoun BC, Collins LC (2015) Predictive markers in breast cancer: an update on ER and Her2 testing and reporting. Semin. Diagn. Pathol. 32: 362–369.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ (2008) Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 26: 729–735.
   PubMed Web of Science ®Google Scholar
• Chandarlapaty S, Sung P, Chen D, He W, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME (2016) cfDNA analysis from BOLERO-2 plasma samples identifies a high rate of ESR1 mutations: exploratory analysis for prognostic and predictive correlation of mutations reveals different efficacy outcomes of endocrine therapy-based regimens. Cancer Res. 76(Suppl. 4): Abstract S2-07 2015 San Antonio Breast Cancer Symposium. http://cancerres.aacrjournals.org/content/76/4_Supplement/S2-07 [accessed 12/05/2016].
   PubMed Web of Science ®Google Scholar
• Chu D, Paoletti C, Gersch C, VanDenBerg DA, Zabransky DJ, Cochran RL, Wong HY, Toro PV, Cidado J, Croessmann S, Erlanger B, Cravero K, Kyker-Snowman K, Button B, Parsons HA, Dalton WB, Gillani R, Medford A, Aung K, Tokudome N, Chinnaiyan AM, Schott A, Robinson D, Jacks KS, Lauring J, Hurley PJ, Hayes DF, Rae JM, Park BH (2016) ESR1 Mutations in circulating plasma tumor DNA from metastatic breast cancer patients. Clin. Cancer Res. 22: 993–999.
   PubMed Web of Science ®Google Scholar
• Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, Perou CM (TCGA Research Network) (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163: 506–519.
   PubMed Web of Science ®Google Scholar
• Clark GM, McGuire WL, Hubay CA, Pearson OH, Carter AC (1983) The importance of estrogen and progesterone receptor in primary breast cancer. Prog. Clin. Biol. Res. 132E: 183–190.
   PubMedGoogle Scholar
• Clinical trials website description of the RxPONDER trial. http://www.clinicaltrials.gov.ezpminer.urmc.rochester.edu/ct2/show/NCT01272037?term=RxPONDER&rank=1 [accessed 10/31/2016].
   Google Scholar
• ClinicalTrials.gov website description of the MINDACT trial. https://clinicaltrials.gov/ct2/show/NCT00433589 [accessed 12/05/2016].
   Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17: 2639–2648.
   PubMed Web of Science ®Google Scholar
• Cohen DA, Dabbs DJ, Cooper KL, Amin M, Jones TE, Jones MW, Chivukula M, Trucco GA, Bhargava R (2012) Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma. Am. J. Clin. Pathol. 138: 796–802.
   PubMed Web of Science ®Google Scholar
• Collins FS, Varmus H (2015) A new initiative on precision medicine. N. Engl. J. Med. 372: 793–795.
   PubMed Web of Science ®Google Scholar
• Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Langone KC, Watson D (2007) Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem. 53: 1084–1091.
   PubMed Web of Science ®Google Scholar
• Cui X, Schiff R, Arpino G, Osborne CK, Lee AV (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J. Clin. Oncol. 23: 7721–7735.
   PubMed Web of Science ®Google Scholar
• Curtis E, Quale C, Haggstrom D, Smith-Bindman R (2008) Racial and ethnic differences in breast cancer survival. How much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer 112: 171–180.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J. Clin. Oncol. 29: 4273–4278.
   PubMed Web of Science ®Google Scholar
• Danforth DN (2013) Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors. Breast Cancer Res. 15: 208.
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R (Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group) (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 38: 805–816.
   Web of Science ®Google Scholar
• Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368: 1199–1209.
   PubMed Web of Science ®Google Scholar
• Denkert C, Kronenwett R, Schlake W, Bohmann K, Penzel R, Weber KE, Höfler H, Lehmann U, Schirmacher P, Specht K, Rudas M, Kreipe HH, Schraml P, Schlake G, Bago-Horvath Z, Tiecke F, Varga Z, Moch H, Schmidt M, Prinzler J, Kerjaschki D, Sinn BV, Müller BM, Filipits M, Petry C, Dietel M (2012) Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch. 460: 251–259.
   PubMed Web of Science ®Google Scholar
• Dent S, Oyan B, Honig A, Mano M, Howell S (2013) HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. Cancer Treat. Rev. 39: 622–631.
   PubMed Web of Science ®Google Scholar
• Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d’Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C (TRANSBIG Consortium) (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 13: 3207–3214.
   PubMed Web of Science ®Google Scholar
• Desmedt C, Giobbie-Hurder A, Neven P, Paridaens R, Christiaens MR, Smeets A, Lallemand F, Haibe-Kains B, Viale G, Gelber RD, Piccart M, Sotiriou C (2009) The gene expression grade index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BioMed Central Med. Genom. 2: 40.
   PubMed Web of Science ®Google Scholar
• Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothé F, Vincent D, Kheddoumi N, Rouas G, Majjaj S, Brohée S, Van Loo P, Maisonneuve P, Salgado R, Van Brussel T, Lambrechts D, Bose R, Metzger O, Galant C, Bertucci F, Piccart-Gebhart M, Viale G, Biganzoli E, Campbell PJ, Sotiriou C (2016) Genomic characterization of primary invasive lobular carcinoma. J. Clin. Oncol. 34: 1872–1881.
   PubMed Web of Science ®Google Scholar
• Dietel M, Johrens K, Laffert MV, Bläker H, Pfitzner BM, Lehmann A, Denkert C, Darb-Esfahani S, Lenze D, Heppner FL, Koch A, Sers C, Klauschen F, Anagnostopoulos I (2015) A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focusing on clinical relevance. Cancer Gene Ther. 22: 417–430.
   PubMed Web of Science ®Google Scholar
• Doherty M, Metcalfe T, Guardino E, Peters E, Ramage L (2016) Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways. Ann. Oncol. 27: 1644–1646.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL, Shak S (2010) Prediction of risk of distant recurrence using the 21-gene Recurrence Score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J. Clin. Oncol. 28: 1829–1834.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J (2013) Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J. Clin. Oncol. 31: 2783–2790.
   PubMed Web of Science ®Google Scholar
• Drukker CA, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van Tinteren H, Wesseling J, Roumen RM, Knauer M, van ’t Veer LJ, Sonke GS, Rutgers EJ, van de Vijver MJ, Linn SC (2013) A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int. J. Cancer 33: 929–936.
   Google Scholar
• Du F, Yuan P, Zhao ZT, Yang Z, Wang T, Zhao JD, Luo Y, Ma F, Wang JY, Fan Y, Cai RG, Zhang P, Li Q, Song YM, Xu BH (2016) A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment. Sci. Rep. 6: 33825.
   PubMed Web of Science ®Google Scholar
• Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group (ABCSG) (2013) The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br. J. Cancer 109: 2959–2964.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, O’Donovan N, McDermott E, Crown J (2016) Validated biomarkers: the key to precision treatment in patients with breast cancer. Breast 29: 192–201.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365: 1687–1717.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379: 432–444.
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486: 353–360.
   PubMed Web of Science ®Google Scholar
• Elsamany S, Elmorsy S, Alzahrani A, Rasmy A, Abozeed WN, Mohammed AA, Sherisher MA, Abbas MM, Mashhour M (2015) Predictive value of IHC4 score for pathological response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer. Asian Pac. J. Cancer Prev. 16: 7975–7979.
   PubMedGoogle Scholar
• Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403–410.
   PubMed Web of Science ®Google Scholar
• Epstein AJ, Wong YN, Mitra N, Vachani A, Hin S, Yang L, Smith-McLallen A, Armstrong K, Groeneveld PW (2015) Adjuvant chemotherapy use and health care costs after introduction of genomic testing in breast cancer. J. Clin. Oncol. 33: 4259–4267.
   PubMed Web of Science ®Google Scholar
• Espinosa E, Vara JA, Redondo A, Sánchez JJ, Hardisson D, Zamora P, Pastrana FG, Cejas P, Martínez B, Suárez A, Calero F, Barón MG (2005) Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study. J. Clin. Oncol. 23: 7278–7285.
   PubMed Web of Science ®Google Scholar
• FDA website MammaPrint® FDA approval 510(k) Substantial Equivalence determination Decision Summary. http://www.accessdata.fda.gov/cdrh_docs/reviews/K062694.pdf [accessed 11/11/2016].
   Google Scholar
• FDA website Prosigna® FDA approval 510(k) Substantial Equivalence determination Decision Summary. http://www.accessdata.fda.gov/cdrh_docs/pdf13/k130010.pdf [accessed 11/11/2016].
   Google Scholar
• Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M (EP Investigators) (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 17: 6012–6020.
   PubMed Web of Science ®Google Scholar
• Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner, H, Margolese R, Poisson R, Shibata H, Volk H (NSABP Investigators) (1983) Relation of the number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52: 1551–1557.
   PubMed Web of Science ®Google Scholar
• Fitzgibbons PL, Hicks DG (2014) Progress in implementing HER2 testing guidelines. Arch. Pathol. Lab. Med. 138: 863–864.
   PubMed Web of Science ®Google Scholar
• Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC (2015) Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 7: 302ra133.
   PubMed Web of Science ®Google Scholar
• Gelbfish GA, Davidson AL, Kopel S, Schreibman B, Gelbfish JS, Degenshein GA, Herz BL, Cunningham JN (1988) Relationship of estrogen and progesterone receptors to prognosis in breast cancer. Ann. Surg. 207: 75–79.
   PubMed Web of Science ®Google Scholar
• Gevensleben H, Göhring UJ, Büttner R, Heukamp LC, Kunz G, Dimpfl T, Jackisch C, Ortmann O, Albert US, Bender R, De Snoo F, Krijgsman O, Glas AM, Ergönenc YH, Vogel C, Dykgers A, Langwieder C, Rees M, Anzeneder T (2010) Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer. Int. J. Mol. Med. 26: 837–843.
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355: 2733–2743.
   PubMed Web of Science ®Google Scholar
• Glück S, Ross JS, Royce M, McKenna EF Jr, Perou CM, Avisar E, Wu (2012) TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine-trastuzumab. Breast Cancer Res. Treat. 132: 781–791.
   PubMed Web of Science ®Google Scholar
• Gluz O, Nitz UA, Christgen M, Kates RE, Clemens M, Kraemer S, Nuding B, Reimer T, Aktas B, Kümmel S, Just M, Stefek A, Lorenz-Salehi F, Krabisch P, Liedtke C, Svedman C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N (2016) Prognostic impact of 21-gene recurrence score, IHC4, and central grade in high-risk HR+/HER2− early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial. J. Clin. Oncol. 34: suppl. abstract 556 ASCO 2016 Annual Meeting. http://meetinglibrary.asco.org/content/168439-176 [accessed 12/05/2016].
   PubMed Web of Science ®Google Scholar
• Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF (Austrian Breast and Colorectal Cancer Study Group) (2014) Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of Recurrence Score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann. Oncol. 25: 339–345.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20: 1319–1329.
   PubMed Web of Science ®Google Scholar
• Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW Jr, Perez EA, Shulman LN, Martino S, Sparano JA (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J. Clin. Oncol. 26: 4063–4071.
   PubMed Web of Science ®Google Scholar
• Goldstein NS, Hewitt SM, Taylor CR, Yaziji H, Hicks DG (Members of ad-Hoc Committee on Immunohistochemistry Standardization) (2007) Recommendations for improved standardization of immunohistochemistry. Appl. Immunohistochem. Mol. Morphol. 15: 124–133.
   PubMedGoogle Scholar
• Gong C, Tan W, Chen K, You N, Zhu S, Liang G, Xie X, Li Q, Zeng Y, Ouyang N, Li Z, Zeng M, Zhuang S, Lau WY, Liu Q, Yin D, Wang X, Su F, Song E (2016) Prognostic value of a BCSC-associated microRNA signature in hormone receptor-positive HER2-negative breast cancer. EBioMedicine 11: 199–209.
   PubMed Web of Science ®Google Scholar
• Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM, Clarke CL (1995) Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res. 55: 5063–5068.
   PubMed Web of Science ®Google Scholar
• Gray RG, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, Poole CJ, Bates T, Chetiyawardana S, Dewar JA, Fernando IN, Grieve R, Nicoll J, Rayter Z, Robinson A, Salman A, Yarnold J, Bathers S, Marshall A, Lee M (aTTom Collaborative Group) (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J. Clin. Oncol. 31: suppl. abstract 5 ASCO 2013 Annual Meeting. http://meetinglibrary.asco.org/content/112995-132 [accessed 12/05/2016].
   Google Scholar
• Győrffy B, Hatzis C, Sanft T, Hofstatter E, Aktas B, Pusztai (2015) Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res. 17: 11.
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (on behalf of the ASCO/CAP Hormone Receptor Testing in Breast Cancer Panel) (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen/progesterone receptors in breast cancer. J. Clin. Oncol. 28: 2784–2795.
   PubMed Web of Science ®Google Scholar
• Hanna WM, Rüschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G (2014) HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod. Pathol. 27: 4–18.
   Web of Science ®Google Scholar
• Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C (Chemo-N 0 Study Group) (2013) Ten year analysis of the prospective multicenter Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur. J. Cancer 49: 1825e35.
   Web of Science ®Google Scholar
• Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF (American Society of Clinical Oncology) (2016) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34: 1134–1150.
   PubMed Web of Science ®Google Scholar
• Heuckmann JM, Thomas RK (2015) A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. Ann. Oncol. 26: 1830–1837.
   PubMed Web of Science ®Google Scholar
• Hicks DG, Boyce BF (2012) The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research. Biotech. & Histochem. 87: 14–17.
   PubMed Web of Science ®Google Scholar
• Hicks DG, Janarthanan BR, Vardarajan R, Kulkarni SA, Khoury T, Dim D, Budd GT, Yoder BJ, Tubbs R, Schreeder MT, Estopinal NC, Beck RA, Wang Y, Ring BZ, Seitz RS, Ross DT (2010) The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence. BioMed Central Cancer 10: 108.
   PubMed Web of Science ®Google Scholar
• Hicks DG, Kulkarni S (2008) HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am. J. Clin. Pathol. 129: 263–273.
   PubMed Web of Science ®Google Scholar
• Hicks DG, Turner B (2015) Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward “precision” cancer therapy. Biotech. & Histochem. 90: 81–92.
   PubMed Web of Science ®Google Scholar
• Hicks DG, Whitney-Miller C (2011) HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge. Appl. Immunohistochem. Mol. Morphol. 19: 506–508.
   PubMedGoogle Scholar
• Hicks DG, Whitney-Miller CL (2013) The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma. Biotech. & Histochem. 88: 121–131.
   PubMed Web of Science ®Google Scholar
• Hicks DG, Kushner L, McCarthy K (2011) Breast cancer predictive factor testing: the challenges and importance of standardizing tissue handling. J. Natl. Cancer Inst. Monogr. 2011: 43–45.
   PubMedGoogle Scholar
• Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Fetting J, Emens L, Riley C, Stearns V, Diehl F, Angenendt P, Huang P, Cope L, Argani P, Murphy KM, Bachman KE, Greshock J, Wolff AC, Park BH (2012) Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin. Cancer Res. 18: 3462–3469.
   PubMed Web of Science ®Google Scholar
• Hornberger J, Chien R, Krebs K, Hochheiser L (2011) US insurance program’s experience with a multigene assay for early-stage breast cancer. J. Oncol. Pract. 7 (Suppl. 3): e38–e45.
   Google Scholar
• Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C (2012) Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J. Clin. Oncol. 30: 1996–2004.
   PubMed Web of Science ®Google Scholar
• Ishibe N, Schullly S, Freedman A, Ramsey SD (2011) Use of Oncotype DX in women with node-positive breast cancer. PLoS Curr. 3: RRN1249.
   PubMedGoogle Scholar
• Jacobs VR, Augustin D, Wischnik A, Kiechle M, Hoess C, Steinkohl O, Rack B, Kapitza T, Krase P (2016) Concordance rates of biomarkers uPA and PAI-1 results in primary breast cancer vs. consecutive tumor board decision and therapy performed in clinical hospital routine: results of a prospective multi-center study at certified breast centers. Breast 29: 208–212.
   PubMed Web of Science ®Google Scholar
• Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstlein R, Fischer T, Schmitt M, Jaenicke F, Untch M, Thomssen C, Harbeck N (2013) Health economic impact of risk group selection according to ASCO recommended biomarkers uPA/PAI-1 in node biomarkers uPA/PAI-1 in node node-negative primary breast cancer. Breast Cancer Res. Treat. 138: 839–850.
   PubMed Web of Science ®Google Scholar
• Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB (2003) Expression profiling of human breast cancers and gene regulation by progesterone receptors. J. Mam. Gland Biol. Neoplasia 8: 257–268.
   PubMed Web of Science ®Google Scholar
• Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M (German N0 Study Group) (2001) Randomized adjuvant chemotherapy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl. Cancer Inst. 93: 913e92.
   Google Scholar
• Jankowitz RC, Cooper K, Erlander MG, Ma XJ, Kesty NC, Li H, Chivukula M, Brufsky A (2011) Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer. Breast Cancer Res. 13: R98.
   PubMed Web of Science ®Google Scholar
• Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R (2015) ESR1 mutations−a mechanism for acquired endocrine resistance in breast cancer. Nat. Rev. Clin. Oncol. 12: 573–583.
   PubMed Web of Science ®Google Scholar
• Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA (2014) Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin. Cancer Res. 20: 1757–1767.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, Alandi T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkio S, Flander M, Helle L, Ingalsuo S, Johansson K, Jaaskelainen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J (FinHer Study Investigators) (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354: 809–820.
   PubMed Web of Science ®Google Scholar
• Jordan VC (1995) Tamoxifen for breast cancer prevention. Proc. Soc. Exp. Biol. Med. 208: 144–149.
   PubMed Web of Science ®Google Scholar
• Jordan VC (2007) New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 72: 829–842.
   PubMed Web of Science ®Google Scholar
• Kalinsky K, Lim EA, Andreopoulou E, Desai AM, Jin Z, Tu Y, Hibshoosh H, Wang A, Greenlee H, Crew KD, Maurer M, Sparano JA, Hershman DL (2014) Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer. Cancer Invest. 32: 439–444.
   PubMed Web of Science ®Google Scholar
• Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 9: 1603–1614.
   PubMed Web of Science ®Google Scholar
• Kim SK, Umbricht CB, Illei PB, Cimino-Mathews A, Cho S, Chowdhury N, Figueroa-Magalhaes MC, Pesce C, Jeter SC, Mylander C, Rosman M, Tafra L, Turner BM, Hicks DG, Jensen TA, Miller DV, Armstrong DK, Connolly RM, Fetting JH, Miller RS, Park BH, Stearns V, Visvanathan K, Wolff AC, Cope L (2016) Optimizing the use of gene expression profiling in early-stage breast cancer. J. Clin. Oncol. doi: 10.1200/JCO.2016.67.7195 [Epub ahead of print].
   Web of Science ®Google Scholar
• Klein ME, Dabbs DJ, Shuai Y, Brufsky AM, Jankowitz R, Puhalla SL, Bhargave R (2013) Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod. Pathol. 26: 658–664.
   PubMed Web of Science ®Google Scholar
• Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, van‘t Veer LJ (2010) The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res. Treat. 120: 655–661.
   PubMed Web of Science ®Google Scholar
• Koscielny S, Tubiana M, Le MG, Valleron AJ, Mouriesse H, Contesso G, Sarrazin D (1984) Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br. J. Cancer 49: 709–715.
   PubMed Web of Science ®Google Scholar
• Kraus WL, Katzenellenbogen BS (1993) Regulation of progesterone receptor gene expression and growth in the rat uterus: modulation of estrogen actions by progesterone and sex steroid hormone antagonists. Endocrinology 132: 2371–2379.
   PubMed Web of Science ®Google Scholar
• Kulkarni SA, Hicks DG, Watroba NL, Murekeyisoni C, Hwang H, Khoury T, Beck RA, Ring BZ, Estopinal NC, Schreeder MT, Seitz RS, Ross DT (2009) TLE3 as a candidate biomarker of response to taxane therapy. Breast Cancer Res. 11: R17.
   Web of Science ®Google Scholar
• Lakhanpal R, Sestak I, Shadbolt B, Bennett GM, Brown M, Phillips T, Zhang Y, Bullman A, Rezo A (2016) IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer. Breast 29: 147–152.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505: 495–501.
   PubMed Web of Science ®Google Scholar
• Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, Pusztai L (2009) Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J. Clin. Oncol. 73: 3185–3191.
   Web of Science ®Google Scholar
• Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, Nielsen TO (2010) Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res. Treat. 119: 53–61.
   PubMed Web of Science ®Google Scholar
• Liu S, Chapman JA, Burnell MJ, Levine MN, Pritchard KI, Whelan TJ, Rugo HS, Albain KS, Perez EA, Virk S, Barry G, Gao D, O’Brien P, Shepherd LE, Nielsen TO, Gelmon KA (2015) Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Breast Cancer Res. Treat. 149: 439–448.
   PubMed Web of Science ®Google Scholar
• Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 25: 1239–1246.
   PubMed Web of Science ®Google Scholar
• Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P, Khandan F, Eidtmann H, Dohnal K, Heinrichs C, Huober J, Pfitzner B, Fasching PA, Andre F, Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C (2014) PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J. Clin. Oncol. 32: 3212–3220.
   PubMed Web of Science ®Google Scholar
• Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O’Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of tumor biological factors uPA and PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. 94: 116–128.
   PubMedGoogle Scholar
• Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P, Sotiriou C, Erlander M, Sgroi D (2008) A five-gene molecular grade index and HOXB13: IL17BRare complementary prognostic factors in early breast cancer. Clin. Cancer Res. 14: 2601–2608.
   PubMed Web of Science ®Google Scholar
• Markopoulos C (2013) Overview of the use of Oncotype DX as an additional treatment decision tool in early breast cancer. Exp. Rev. Anticancer Ther. 13: 179–194.
   PubMed Web of Science ®Google Scholar
• Markopoulos C, van de Velde C, Zarca D, Ozmen V, Masetti R (2016) Clinical evidence supporting genomic tests in early breast cancer: do all genomic tests provide the same information? Eur. J. Surg. Oncol. pii: S0748-7983(16)30857-5. [Epub ahead of print].
   PubMedGoogle Scholar
• McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS Sr (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med. 109: 716–721.
   PubMed Web of Science ®Google Scholar
• Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, Yelensky R, Brown M, Miller VA, Sarid D, Rizel S, Klein B, Rubinek T, Wolf I (2013) D538G mutation in estrogen receptor-α: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 73: 6856–6864.
   PubMed Web of Science ®Google Scholar
• Metzger-Filho O, Ignatiadis M, Sotiriou C (2011) Genomic Grade Index: an important tool for assessing breast cancer tumor grade and prognosis. Crit. Rev. Oncol. Hematol. 77: 20–29.
   PubMed Web of Science ®Google Scholar
• Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delrée P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart M, Sotiriou C (2013) Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer. PLoS One 8: e66848.
   PubMed Web of Science ®Google Scholar
• Middleton LP, Price KM, Puig P, Heydon LJ, Tarco E, Sneige N, Barr K, Deavers MT (2009) Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch. Pathol. Lab. Med. 133: 775–780.
   PubMed Web of Science ®Google Scholar
• Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van’t Veer LJ (TRANSBIG Consortium) (2009) The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res. Treat. 116: 295–302.
   PubMed Web of Science ®Google Scholar
• Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJ, van ’t Veer LJ (2010) The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann. Oncol. 21: 717–722.
   PubMed Web of Science ®Google Scholar
• Morris GJ, Mitchell EP (2008) Higher incidence of aggressive breast cancers in African-American women: a review. J. Natl. Med. Assoc. 100: 698–702.
   PubMed Web of Science ®Google Scholar
• Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S (2011) High genomic grade index associated with poor prognosis for lymph node-negative and estrogen receptor-positive breast cancers and with good response to chemotherapy. Cancer 73: 472–479.
   Web of Science ®Google Scholar
• Neumeister VM, Anagnostou V, Siddiqui S, England AM, Zarrella ER, Vassilakopoulou M, Parisi F, Kluger Y, Hicks DG, Rimm DL (2012) Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J. Natl. Cancer Inst. 104: 1815–1824.
   PubMedGoogle Scholar
• Nielsen T, Wallden B, Schaper C, Ferree S, Liu S, Gao D, Barry G, Dowidar N, Maysuria M, Storhoff J (2014) Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BioMed Central Cancer 14: 177.
   PubMed Web of Science ®Google Scholar
• Nunes RA, Wray L, Mete M, Herbolsheimer P, Smith KL, Bijelic L, Boisvert ME, Swain SM (2016) Genomic profiling of breast cancer in African-American women using MammaPrint. Breast Cancer Res. Treat. 159: 481–488.
   PubMed Web of Science ®Google Scholar
• Oncomark website. http://www.oncomark.com/go/products/oncomastr [accessed 11/07/16].
   Google Scholar
• Owens MA, Horten BC, Da Silve MM (2004) HER2 amplification rates by fluorescence in situ hybridization and correlation with immunohistochemistry in cohort of 6557 breast cancer tissue. Clin. Breast Cancer 5: 63–69.
   PubMedGoogle Scholar
• Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Walmart N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node negative breast cancer. N. Engl. J. Med. 351: 2817–2826.
   PubMed Web of Science ®Google Scholar
• Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Constantine JP, Geyer CE Jr, Wickerham DL, Walmart N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24: 3726–3734.
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27: 1160–1167.
   PubMed Web of Science ®Google Scholar
• Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ (2013) Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res. Treat. 138: 99–108.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406: 747–752.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (Herceptin Adjuvant (HERA) Trial Study Team) (2005) Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer. N. Engl. J. Med. 353: 1659–1672.
   PubMed Web of Science ®Google Scholar
• Precision Medicine Initiative (PMI) Working Group Report to the Advisory Committee to the Director, NIH (2015) https://www.nih.gov/sites/default/files/research-training/initiatives/pmi/pmi-working-group-report-20150917-2.pdf [accessed 11/30/2016].
   Google Scholar
• Prosigna® [Package Insert] (2013) NanoString Technologies, Inc., Seattle, WA. http://prosigna.com/wp-content/uploads/2016/09/LBL_C02223_06_Package-Insert-Prosigna-Assay-US.pdf [accessed 12/05/2016].
   Google Scholar
• Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol. 19: 980–991.
   PubMed Web of Science ®Google Scholar
• Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J. Biol. Chem. 277: 5209–5218.
   PubMed Web of Science ®Google Scholar
• Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC, Yoder BJ, Budd GT, Nielsen TO, Hicks DG, Estopinal NC, Ross DT (2006) Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J. Clin. Oncol. 24: 3039–3047.
   PubMed Web of Science ®Google Scholar
• Robinson BD, Sica GL, Liu YF, Rohan TE, Gertler FB, Condeelis JS, Jones JG (2009) Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin. Cancer Res. 15: 2433–2441.
   PubMed Web of Science ®Google Scholar
• Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, Roychowdhury S, Pienta KJ, Kim SY, Roberts JS, Rae JM, Van Poznak CH, Hayes DF, Chugh R, Kunju LP, Talpaz M, Schott AF, Chinnaiyan AM (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45: 1446–1451.
   PubMed Web of Science ®Google Scholar
• Rohan TE, Xue X, Lin HM, D’Alfonso TM, Ginter PS, Oktay MH, Robinson BD, Ginsberg M, Gertler FB, Glass AG, Sparano JA, Condeelis JS, Jones JG (2014) Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. J. Natl. Cancer Inst. 106 : dju136. doi: 10.1093/jnci/dju136.
   Google Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353: 1673–1684.
   PubMed Web of Science ®Google Scholar
• Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, Rathi V, Fehrenbacher L, Brufsky A, Azar CA, Flynn PJ, Zapas JL, Polikoff J, Gross HM, Biggs DD, Atkins JN, Tan-Chiu E, Zheng P, Yothers G, Mamounas EP, Wolmark N (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 30: 3792–3799.
   PubMed Web of Science ®Google Scholar
• Ross JS, Fletcher JA (2008) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3: 237–252.
   Google Scholar
• Ross DT, Kim CY, Tang G, Bohn OL, Beck RA, Ring BZ, Seitz RS, Paik S, Costantino JP, Wolmark N (2008) Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clin. Cancer Res. 14: 6602–6609.
   PubMed Web of Science ®Google Scholar
• Rouzier R, Pronzato P, Chéreau E, Carlson J, Hunt B, Valentine WJ (2013) Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Res. Treat. 139: 621–637.
   PubMed Web of Science ®Google Scholar
• Sartorius CA, Shen T, Horwitz KB (2003) Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. Breast Cancer Res. Treat. 79: 287–299.
   PubMed Web of Science ®Google Scholar
• Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, Cuzick J (2013) Factors predicting late recurrence for estrogen receptor-positive breast cancer. J. Natl. Cancer Inst. 105: 1504–1511.
   PubMed Web of Science ®Google Scholar
• Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M (2013) Prediction of late distant recurrence in patients with oestrogen-receptor positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study. Lancet Oncol. 14: 1067–1076.
   PubMed Web of Science ®Google Scholar
• Sheppard VB, Mays D, LaVeist T, Tercyak KP (2013) Medical mistrust and self-efficacy influence black women’s level of engagement in BRCA1/2 genetic counseling and testing. J. Natl. Med. Assoc. 105: 17–22.
   PubMed Web of Science ®Google Scholar
• Simpson PT, Reis-Filho JS, Gale T, Lakhani SR (2005) Molecular evolution of breast cancer. J. Pathol. 205: 248–254.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344: 783–792.
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 98: 262–272.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW (2015) Prospective validation of a 21-gene expression assay in breast cancer. N. Engl. J. Med. 373: 2005–2014.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26: 721–728.
   PubMed Web of Science ®Google Scholar
• Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, Easton D, Langerød A; Oslo Breast Cancer Consortium (OSBREAC), Lee MT, Shen CY, Tee BT, Huimin BW, Broeks A, Vargas AC, Turashvili G, Martens J, Fatima A, Miron P, Chin SF, Thomas G, Boyault S, Mariani O, Lakhani SR, van de Vijver M, van ’t Veer L, Foekens J, Desmedt C, Sotiriou C, Tutt A, Caldas C, Reis-Filho JS, Aparicio SA, Salomon AV, Børresen-Dale AL, Richardson AL, Campbell PJ, Futreal PA, Stratton MR (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400–404.
   PubMed Web of Science ®Google Scholar
• Stonelake PS, Bundred NJ, Neoptolemos NP, Baker PR, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM, Bundred NJ, Oates GD, Stonelake PS, Lee MJR, Neoptolemos JP, Chan SY (1994) Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur. J. Cancer 30: 5–11.
   Web of Science ®Google Scholar
• Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG, Tang P (2010) The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl.) 4: 35–41.
   PubMedGoogle Scholar
• Sweep CG, Geurts-Moespot J, Grebenschikov N, de Witte JH, Heuvel JJ, Schmitt M, Duffy MJ, Jänicke F, Kramer MD, Foekens JA, Brünner N, Brugal G, Pedersen AN, Benraad TJ (1998) External quality assessment of trans-European multicenter antigen determination (enzyme-linked immunosorbent assay) of urokinase plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer extracts. Br. J. Cancer 78: 1434–1441.
   PubMed Web of Science ®Google Scholar
• Tang P, Desmedt C, Hicks DG (2015) Breast cancer diagnosis: past, present and future. Dako White Paper: 1–51.
   Google Scholar
• Tang P, Skinner KA, Hicks DG (2009) Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn. Mol. Pathol. 18: 125–132.
   PubMed Web of Science ®Google Scholar
• Tang P, Wang J, Hicks DG, Wang X, Schiffhauer L, McMahon L, Yang Q, Shayne M, Huston A, Skinner KA, Griggs J, Lyman G (2010) A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest. 28: 978–982.
   PubMed Web of Science ®Google Scholar
• Tang Y, Zhou X, Ji J, Chen L, Cao J, Luo J, Zhang S (2015) High expression levels of miR-21 and miR-210 predict unfavorable survival in breast cancer: a systemic review and meta-analysis. Int. J. Biol. Markers 30: e347–e358.
   PubMed Web of Science ®Google Scholar
• Tariq K, Latif N, Zaiden R, Jasani N, Rana F (2013) Breast cancer and racial disparity between Caucasian and African-American women, part 1 (BRCA-1). Clin. Adv. Hematol. Oncol. 11: 505–509.
   PubMedGoogle Scholar
• Taylor CR (2007) Editorial—a personal perspective. Appl. Immunohistochem. Mol. Morphol. 15: 121–123.
   PubMedGoogle Scholar
• Tian S, Roepman P, Van’t Veer LJ, Bernards R, de Snoo F, Glas AM (2010) Biological functions of the genes in the Mammaprint breast cancer profile reflect the hallmarks of cancer. Biomark. Insights 5: 129–138.
   PubMedGoogle Scholar
• Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BioMed Central Cancer 7: 134.
   PubMed Web of Science ®Google Scholar
• Torsten A. Hopp, HL. Weiss, SG (2004) Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin. Cancer Res. 15: 2751–2760.
   Google Scholar
• Toussaint J, Sieuwerts AM, Haibe-Kains B, Desmedt C, Rouas G, Harris AL, Larsimont D, Piccart M, Foekens JA, Durbecq V, Sotiriou C (2009) Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin embedded tissues. BioMed Central Genomics 10: 424.
   Google Scholar
• Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45: 1439–1445.
   PubMed Web of Science ®Google Scholar
• Turner BM, Skinner KA, Tang P, Jackson MC, Soukiazian N, Shayne M, Huston A, Ling M, Hicks DG (2015) Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Mod. Pathol. 28: 921–931.
   PubMed Web of Science ®Google Scholar
• Turner B, Soukiazian N, Tang P, Hicks DG (2016a) Validation of the Rochester University Modified Magee Algorithm (RUMMA) for risk stratification of estrogen receptor positive breast cancer patients. Mod. Pathol. 29: 75A–76A, abstract 295 2016 USCAP conference. http://www.nature.com/modpathol/journal/v29/n2s/pdf/modpathol20163a.pdf [accessed 12/05/2016].
   PubMed Web of Science ®Google Scholar
• Turner B, Soukiazian N, Tang P, Hicks DG (2016b) Progesterone receptor and Ki-67 discordance in African American women with hormone receptor positive breast cancer submitted for Oncotype DX testing. Mod. Pathol. 29: 76A abstract 295 2016 USCAP conference. http://www.nature.com/modpathol/journal/v29/n2s/pdf/modpathol20163a.pdf
   Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347: 1999–2009.
   PubMed Web of Science ®Google Scholar
• van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–536.
   PubMed Web of Science ®Google Scholar
• Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, Obermann E, Ohlschlegel C, Padberg B, Rakozy C, Sancho Oliver S, Schobinger-Clement S, Schreiber-Facklam H, Singer G, Tapia C, Wagner U, Mastropasqua MG, Viale G, Lehr HA (2012) How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast and Gynecopathologists. PLoS One 7: e37379.
   PubMed Web of Science ®Google Scholar
• Vergara-Lluri ME, Moatamed NA, Hong E, Apple SK (2012) High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines. Mod. Pathol. 25: 1326–1332.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367: 1783–1791.
   PubMed Web of Science ®Google Scholar
• Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 28: 1684–1691.
   PubMed Web of Science ®Google Scholar
• Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA (2005) Gene-expression profiles to predict distant metastasis of lymph node-negative primary breast cancer. Lancet 365: 671–679.
   PubMed Web of Science ®Google Scholar
• Ward S, Scope A, Rafia R, Pandor A, Harnan S, Evans P, Wyld L (2013) Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis. Health Technol. Assess. 17: 1–302.
   PubMed Web of Science ®Google Scholar
• Wei LL, Norris BM, Baker CJ (1997) An N-terminally truncated third progesterone receptor protein, PRC, forms heterodimers with PRB but interferes in PRB-DNA binding. J. Ster. Biochem. Mol. Biol. 62: 287–297.
   PubMed Web of Science ®Google Scholar
• Weir HM, Bradbury RH, Lawson M, Rabow AA, Buttar D, Callis RJ, Curwen JO, de Almeida C, Ballard P, Hulse M, Donald CS, Feron LJ, Karoutchi G, MacFaul P, Moss T, Norman RA, Pearson SE, Tonge M, Davies G, Walker GE, Wilson Z, Rowlinson R, Powell S, Sadler C, Richmond G, Ladd B, Pazolli E, Mazzola AM, D’Cruz C, De Savi C (2016) AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER positive and ESR1-mutant breast tumors in preclinical models. Cancer Res. 76: 3307–3318.
   PubMed Web of Science ®Google Scholar
• Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, Dahiya S, Habin K, Bernards R, Haber DA, Van’t Veer LJ, Ramaswamy S (2008) Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin. Cancer Res. 14: 2988–2993.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (AmericanSociety of Clinical Oncology; College of American Pathologists) (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25: 118–145.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (American Society of Clinical Oncology; College of American Pathologists) (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch. Pathol. Lab. Med. 138: 241–256.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Baselga J, Miles D (2004) Molecular approach to breast cancer treatment. Semin. Oncol. 31 (Suppl. 10): 6–13.
   PubMed Web of Science ®Google Scholar
• Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM (2004) HER-2 testing in breast cancer using parallel tissue-based methods. J. Am. Med. Assoc. 291: 1972–1977.
   PubMed Web of Science ®Google Scholar
• Yaziji H, Taylor CR, Goldstein NS, Dabbs DJ, Hammond EH, Hewlett B, Floyd AD, Barry TS, Martin AW, Badve S, Baehner F, Cartun RW, Eisen RN, Swanson PE, Hewitt SM, Vyberg M, Hicks DG (Members of the standardization ad-hoc consensus committee) (2008) Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl. Immunohistochem. Mol. Morphol. 16: 513–520.
   PubMedGoogle Scholar
• Yeo B, Zabaglo L, Hills M, Dodson A, Smith I, Dowsett M (2015) Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study. Br. J. Cancer 113: 390–395.
   PubMed Web of Science ®Google Scholar
• Yildiz-Aktas IZ, Dabbs DJ, Cooper KL, Chivukula M, McManus K, Bhargava R (2012) The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Am. J. Clin. Pathol. 137: 691–698.
   PubMed Web of Science ®Google Scholar
• Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, Lawrence MS, Zhsng CZ, Wala J, Mermel CH, Sougnez C, Gabriel SB, Hernandez B, Shen H, Laird PW, Getz G, Meyerson M, Beroukhim R (2013) Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45: 1134–1140.
   PubMed Web of Science ®Google Scholar